These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 35841520)

  • 41. Motor complications in an incident Parkinson's disease cohort.
    Scott NW; Macleod AD; Counsell CE
    Eur J Neurol; 2016 Feb; 23(2):304-12. PubMed ID: 26074125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale for current therapies in Parkinson's disease.
    Romrell J; Fernandez HH; Okun MS
    Expert Opin Pharmacother; 2003 Oct; 4(10):1747-61. PubMed ID: 14521485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R; Lyons KE
    Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2014 Jan; 11(1):34-46. PubMed ID: 24310604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert.
    Kulisevsky J
    Rev Neurol; 2022 Oct; 75(s04):S1-S10. PubMed ID: 36342310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Levodopa in the treatment of Parkinson's disease: myths and realties].
    Luquin MR; García-Ruiz PJ; Martí MJ; Rojo A; Vela L; Grandas FJ; Bravo-Utrera M; Burguera JA; Chacón JR; Campos-Arillo VM; Durán-Herrera C; Fernández-García JM; García-Ramos R; Gómez-Esteban JC; Gutierrez J; Juni J; Mata M; Martínez-Castrillo JC; Olivares J; Ribacoba-Montero R; Santos-García D; Sierra M; Valero-Merino C
    Rev Neurol; 2012 Dec; 55(11):669-88. PubMed ID: 23172094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.
    Kianirad Y; Simuni T
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):34. PubMed ID: 26898686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levodopa in the treatment of Parkinson's disease.
    Fahn S
    J Neural Transm Suppl; 2006; (71):1-15. PubMed ID: 17447410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic and pharmacologic perspectives in Parkinson's disease].
    Corvol JC; Mariani LL
    Rev Prat; 2018 May; 68(5):515-519. PubMed ID: 30869416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.